Afuresertib (GSK2110183)

For research use only.

Catalog No.S7521

14 publications

Afuresertib (GSK2110183) Chemical Structure

CAS No. 1047644-62-1

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

Size Price Stock Quantity  
EUR 144 In stock
EUR 468 In stock
EUR 979 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Afuresertib (GSK2110183) has been cited by 14 publications

1 Customer Review

  • Analysis of the mechanism of action of the enhanced anti‑tumor effect of the combination therapy of suboptimal doses of pomalidomide plus dexamethasone and afuresertib in MM cells. (A‑C) The altered expression of protein substrates was analyzed in two MM cell lines that were treated with suboptimal doses of PD, or AFU, or the PD and AFU combination. The XG‑7 and U266 cell lines were subjected to the indicated treatments for 48 and 72 h, respectively. (A) Caspases, (B) substrates related mainly to the working mechanism of IMiDs, (C) substrates mainly related to the working mechanism of afuresertib, and (D) two primary MM cell cultures, were subjected to the analysis in the same manner as the two MM cell lines. In the expression panel of p‑FoxO3a/FoxO1, the upper band represents p‑FoxO3a and the lower band represents p‑FOXO1. PD, pomalidomide plus dexamethasone; AFU, Afuresertib; MM, multiple myeloma; IMiDs, immunomodulatory drugs.

    ONCOLOGY LETTERS, 2018, https://doi.org/10.3892/ol.2018.8501. Afuresertib (GSK2110183) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
0.08 nM(Ki) 2 nM(Ki) 2.6 nM(Ki)
In vitro

Afuresertib inhibits the kinase activity of the E17K AKT1 mutant protein with EC50 of 0.2 nM. Afuresertib shows a concentration-dependent effect on multiple AKT substrate phosphorylation levels, including GSK3b, PRAS40, FOXO and Caspase 9. Overall 65% of the hematological cell lines are sensitive to afuresertib (EC50 < 1 μM). Among tested solid tumor cell lines, 21% have EC50 < 1 μM in response to afuresertib.[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 NYTUeHFjTnWwY4Tpc44h[XO|YYm= MYW0NEBucW6| MYHJcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIHj1cYFvKEGNVEGg[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4he3Wkc4TyZZRmKHCqb4PwbI9zgWyjdHnvckB2e2mwZzDibY91cW5vYXj4MWFTU1KHUlHZV2ZIUEiDLXHtbYRmKHO3YoP0doF1\SCjbnSgX4didW2jLUOzVH1CXFBiaX7jeYJifGWmIH\vdkA1OCCvaX7zJIJ6KHSxcDDjc5VvfCCvaXPyc5Bt[XSnIIPjbY51cWyuYYTpc44h[2:3boTpcochdWW2aH;kMEBKSzVyIE2gNE4xODFizszNMi=> M{\mRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
Sf9 MmLjSpVv[3Srb36gZZN{[Xl? NHrGZYo1OCCvaX7z NF;n[ppKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJIh2dWGwIFHLWFMh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5ic4Xid5Rz[XSnIIDoc5NxcG:{eXzheIlwdiC3c3nu[{BjcW:2aX6tZYh5NUGUS2LFVmF[W0[JSFjBMYFucWSnIIP1ZpN1emG2ZTDhcoQhY2ejbX3hMVM{WF2DVGCgbY5kfWKjdHXkJIZweiB2MDDtbY5{KGK7IITvdEBkd3WwdDDtbYNzd3CuYYTlJJNkcW62aXzsZZRqd25iY3;1cpRqdmdibXX0bI9lNCCLQ{WwJF0hOC5yMEG1PFUh|ryPLh?= NIrneWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
COLO205 NFTuWXBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX;Ld5pEPzJiaILz NFziZVVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBEV0yRMkC1JINmdGy|IHH0JFE7OTBibX;sZZIhemG2aX:gc4Yh[2:vcH;1coQhcW5icILld4Vv[2Vib3[gUk18Oy2dMz3jfYNtd3C{b4D5cE02NSh{LX\seY9zdy12LXnv[I8ueGinbonsZY1qdm9rLU[sPE1lcW2ndHj5cE0hOix2LEeteJJqd3ixLUOsOEw3NDdvdHX0doFpgWS{bz2yTE1xgXKrZH;bOEw{NWSfcInybY1q\GmwLUGtfYxeeGinbonsgYFk\XSjbXnk[UBqdmO3YnH0[YQh\m:{IEeyJIhzeyBuIFnDOVAhRSByLkCwPUDPxE1w MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
Sf9 MlzlSpVv[3Srb36gZZN{[Xl? M{nBfVQxKG2rboO= MX3Jcohq[mm2aX;uJI9nKG[3bHygcIVv\3SqIHj1cYFvKEGNVEKg[ZhxemW|c3XkJIlvKFOoOTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4he3Wkc4TyZZRmKHCqb4PwbI9zgWyjdHnvckB2e2mwZzDibY91cW5vYXj4MWFTU1KHUlHZV2ZIUEiDLXHtbYRmKHO3YoP0doF1\SCjbnSgX4didW2jLUOzVH1CXFBiaX7jeYJifGWmIH\vdkA1OCCvaX7zJIJ6KHSxcDDjc5VvfCCvaXPyc5Bt[XSnIIPjbY51cWyuYYTpc44h[2:3boTpcochdWW2aH;kMEBKSzVyIE2gNE4xOSEQvF2u M{j5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
MV522 MoTBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHnBTHA4OiCqcoO= NWHkWHE{T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVVZ3MkKgZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{NCCLQ{WwJF0hOC5yMUKg{txONg>? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
HT-29 NYTYW4lmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXW3NkBpenN? MYHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIWE0zQSClZXzsd{BifCBzOkGwJI1wdGG{IILheIlwKG:oIHPvcZBwfW6mIHnuJJBz\XOnbnPlJI9nKE5ve{OtX|Mu[3mlbH;wdo9xgWxvNT2oNk1ndHWxcn:tOE1qd2SxLYDo[Y56dGGvaX7vLU03NDhvZHnt[ZRpgWxvIEKsOEw4NXS{aX;4c{0{NDRuNjy3MZRmfHKjaInkdo8uOkhvcInybYRwYzRuMz3kYZB6emmvaXTpck0yNXmuXYDo[Y56dH2jY3X0ZY1q\GViaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCwMlAyPSEQvF2u M1ziO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
NCI-H727 NWe0dFhKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX[3NkBpenN? MmXSS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUh5MkegZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{NCCLQ{WwJF0hOC5yMUmg{txONg>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
SW1417 MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYTPbGpCPzJiaILz NHS1WnFIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUXzF2MUegZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{NCCLQ{WwJF0hOC5yMzFOwG0v M4jpTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
Calu6 MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYC3NkBpenN? MlO2S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gR4FtfTZiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4xOzFizszNMi=> M{i2SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
LS1034 M3fqb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MonBO|IhcHK| M3PuXmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGxUOTB|NDDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjB2IN88UU4> MmrJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
SW1463 MlfuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmT5O|IhcHK| Mlz0S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV3cyPDZ|IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvODRzIN88UU4> NH3MflQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
RKO Mn3ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH;NSGo4OiCqcoO= NED4bFVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBTU09iY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4xPTRizszNMi=> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
NCI-H508 NEG5dHRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVe2bVYxPzJiaILz MXrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDVyODDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjB6IN88UU4> NGL3dFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
NCI-H1155 NYWzWFhMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWnmPJZXPzJiaILz MYTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDFzNUWgZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJItKEmFNUCgQUAxNjFyMTFOwG0v NH3KOHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
A427 NFjmWY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX63NkBpenN? NHfQ[VlIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvOTB|IN88UU4> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
KM12 MlfLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{e2bVczKGi{cx?= MVTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDLUVEzKGOnbHzzJIF1KDF8MUCgcY9t[XJicnH0bY8hd2ZiY3;tdI92dmRiaX6gdJJme2WwY3Wgc4YhVi29Mz3bN{1kgWOub4Dyc5B6dC13LTiyMYZtfW:{bz20MYlw\G9vcHjlcplt[W2rbn:pMVYtQC2maX3leIh6dC1iMjy0MFcufHKrb4jvMVMtPCx4LEeteIV1emGqeXTyc{0zUC2yeYLp[I9cPCx|LXTddJlzcW2rZHnuMVEugWyfcHjlcplthWGlZYThcYll\SCrbnP1ZoF1\WRiZn;yJFczKGi{czygTWM2OCB;IECuNVA1KM7:TT6= M3THXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
HCT8 MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWP2c2ZpPzJiaILz MVrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3Q5KGOnbHzzJIF1KDF8MUCgcY9t[XJicnH0bY8hd2ZiY3;tdI92dmRiaX6gdJJme2WwY3Wgc4YhVi29Mz3bN{1kgWOub4Dyc5B6dC13LTiyMYZtfW:{bz20MYlw\G9vcHjlcplt[W2rbn:pMVYtQC2maX3leIh6dC1iMjy0MFcufHKrb4jvMVMtPCx4LEeteIV1emGqeXTyc{0zUC2yeYLp[I9cPCx|LXTddJlzcW2rZHnuMVEugWyfcHjlcplthWGlZYThcYll\SCrbnP1ZoF1\WRiZn;yJFczKGi{czygTWM2OCB;IECuNVQ{KM7:TT6= NVvUVIVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
MDA-MB-175-VII NUPrNG4yT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3TVVFczKGi{cx?= MnzFS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWRCNU2ELUG3OU1XUUliY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4yPTVizszNMi=> NI[xOZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
A549 M3\Vd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYntdIVEPzJiaILz NHyxNVZIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvOTZ2IN88UU4> NVjmVIpxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
NCI-H23 M3[2dGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NELFPVA4OiCqcoO= NICze4hIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKzJINmdGy|IHH0JFE7OTBibX;sZZIhemG2aX:gc4Yh[2:vcH;1coQhcW5icILld4Vv[2Vib3[gUk18Oy2dMz3jfYNtd3C{b4D5cE02NSh{LX\seY9zdy12LXnv[I8ueGinbonsZY1qdm9rLU[sPE1lcW2ndHj5cE0hOix2LEeteJJqd3ixLUOsOEw3NDdvdHX0doFpgWS{bz2yTE1xgXKrZH;bOEw{NWSfcInybY1q\GmwLUGtfYxeeGinbonsgYFk\XSjbXnk[UBqdmO3YnH0[YQh\m:{IEeyJIhzeyBuIFnDOVAhRSByLkG5PUDPxE1w MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
SW837 MkHhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWC3NkBpenN? MojRS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV3c5OzdiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4zPDhizszNMi=> M3rwPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
SW480 MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnnEO|IhcHK| MVrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTW|Q5OCClZXzsd{BifCBzOkGwJI1wdGG{IILheIlwKG:oIHPvcZBwfW6mIHnuJJBz\XOnbnPlJI9nKE5ve{OtX|Mu[3mlbH;wdo9xgWxvNT2oNk1ndHWxcn:tOE1qd2SxLYDo[Y56dGGvaX7vLU03NDhvZHnt[ZRpgWxvIEKsOEw4NXS{aX;4c{0{NDRuNjy3MZRmfHKjaInkdo8uOkhvcInybYRwYzRuMz3kYZB6emmvaXTpck0yNXmuXYDo[Y56dH2jY3X0ZY1q\GViaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCwMlI2QSEQvF2u NXPFfFlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
NCI-H1355 NEnZ[|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmWzO|IhcHK| NGP4fIVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGzOVUh[2WubIOgZZQhOTpzMDDtc4xieiC{YYTpc{Bw\iClb33wc5Vv\CCrbjDwdoV{\W6lZTDv[kBPNXt|LWuzMYN6[2yxcILvdJltNTVvKEKt[ox2d3KxLUStbY9ldy2yaHXufYxidWmwbzmtOkw5NWSrbXX0bJltNSB{LESsO{11emmxeH:tN{w1NDZuNz30[ZRz[Wi7ZILvMVJJNXC7cnnkc3s1NDNvZG3wfZJqdWmmaX6tNU16dF2yaHXufYx:[WOndHHtbYRmKGmwY4XiZZRm\CCob4KgO|IhcHJuIFnDOVAhRSByLkK2PEDPxE1w Mof1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
EFM19 NFf6W3NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M13xOVczKGi{cx?= MofCS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSWZOOTliY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4{KM7:TT6= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
T84 MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXG3NkBpenN? M1GyV2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHQ5PCClZXzsd{BifCBzOkGwJI1wdGG{IILheIlwKG:oIHPvcZBwfW6mIHnuJJBz\XOnbnPlJI9nKE5ve{OtX|Mu[3mlbH;wdo9xgWxvNT2oNk1ndHWxcn:tOE1qd2SxLYDo[Y56dGGvaX7vLU03NDhvZHnt[ZRpgWxvIEKsOEw4NXS{aX;4c{0{NDRuNjy3MZRmfHKjaInkdo8uOkhvcInybYRwYzRuMz3kYZB6emmvaXTpck0yNXmuXYDo[Y56dH2jY3X0ZY1q\GViaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCwMlMxPCEQvF2u NEjSPHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
COR-L23 MmrQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVy3NkBpenN? MUXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDU3IuVDJ|IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{AtKEmFNUCgQUAxNjN4ODFOwG0v NYKzWVRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
NCI-H1792 NHHqSmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{XmXlczKGi{cx?= M{DuWGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe5NkBk\WyuczDheEAyQjFyIH3vcIFzKHKjdHnvJI9nKGOxbYDveY5lKGmwIIDy[ZNmdmOnIH;mJG4ugzNvW{OtZ5lkdG:ycn;wfYwuPS1qMj3mcJVwem9vND3pc4RwNXCqZX75cIFucW6xKT22MFgu\GmvZYTofYwuKDJuNDy3MZRzcW:6bz2zMFQtPix5LYTleJJicHmmcn:tNmgueHm{aXTvX|QtOy2mXYD5dolucWSrbj2xMZltZXCqZX75cJ1i[2W2YX3p[IUhcW6ldXLheIVlKG[xcjC3NkBpeixiSVO1NEA:KDBwM{e0JO69VS5? NVu0S3llRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
SW1573 MmfGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MU[3NkBpenN? MkXxS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV3cyPTd|IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvOzh{IN88UU4> NEjPVXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
Calu3 NXL0TJRlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4K4clczKGi{cx?= MX;Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDZYx2OyClZXzsd{BifCBzOkGwJI1wdGG{IILheIlwKG:oIHPvcZBwfW6mIHnuJJBz\XOnbnPlJI9nKE5ve{OtX|Mu[3mlbH;wdo9xgWxvNT2oNk1ndHWxcn:tOE1qd2SxLYDo[Y56dGGvaX7vLU03NDhvZHnt[ZRpgWxvIEKsOEw4NXS{aX;4c{0{NDRuNjy3MZRmfHKjaInkdo8uOkhvcInybYRwYzRuMz3kYZB6emmvaXTpck0yNXmuXYDo[Y56dH2jY3X0ZY1q\GViaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCwMlM6OiEQvF2u NEjlSYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
HCC827 NFrZNGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVT4bXY5PzJiaILz MYDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR2M5OjdiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE41ODFizszNMi=> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
EFM19 MoPTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1rW[|czKGi{cx?= MWfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDFSm0yQSClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDD[YxtNXSrdHXyMWdtdyC{ZXHn[Y51KGKjc3XkJIF{e2G7LDDJR|UxKD1iMD60N{DPxE1w M3;MSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
HOP62 M3L1Xmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NG\JSnk4OiCqcoO= NHG1OVRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJV1B4MjDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjR7ODFOwG0v NYrp[pdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
NCI-H508 MoTwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4HqNFczKGi{cx?= M4naTGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUC4JINmdGy|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUAxNjV{MjFOwG0v NVnl[lBGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
SW900 M1H5NWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUDs[GgxPzJiaILz NIKzcI9Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUXzlyMDDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjdzOTFOwG0v MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
MDA-MB-175-VII MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXG3NkBpenN? M4Dscmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xO|UuXkmLIHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO|YYmsJGlEPTBiPTCwMlc6PCEQvF2u M4fzblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
NCI-H1155 NWq4[XVbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn7EO|IhcHK| NH3Mc29Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGxOVUh[2WubIOgbY5kfWKjdHXkJIZweiB5MjDodpMh[nliQ3XscE11cXSncj3HcI8hemWjZ3XueEBj[XOnZDDhd5NigSxiSVO1NEA:KDBwOE[1JO69VS5? Mk[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
DLD1 NF7UU4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVLkSIFlPzJiaILz NXvRUoo4T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTEyGMTDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjl|MjFOwG0v NWq2dGhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
HT-29 M4\LV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGC0TVI4OiCqcoO= MoPaS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTHQuOjliY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR4VtdC22aYTldk1IdG9icnXh[4VvfCCkYYPl[EBie3OjeTygTWM2OCB;IEGuN|g{KM7:TT6= MnPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
HCT8 MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEDRN3M4OiCqcoO= MUDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3Q5KGOnbHzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IFPlcIwufGm2ZYKtS4xwKHKnYXflcpQh[mG|ZXSgZZN{[XluIFnDOVAhRSBzLkW0NUDPxE1w NWHrcVRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
RKO MoHHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHi4XJc4OiCqcoO= NYfrPXpRT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO|YYmsJGlEPTBiPTCxMlgxPiEQvF2u NFrPR4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
Calu6 NFrXeW5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVvCNXAzPzJiaILz M3HCXGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGNidHV4IHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO|YYmsJGlEPTBiPTCyMlE2PCEQvF2u MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
KM12 M2HFUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn7PO|IhcHK| NUSz[4JDT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hU01zMjDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBE\WyuLYTpeIVzNUeubzDy[YFo\W62IHLhd4VlKGG|c3H5MEBKSzVyIE2gNk4zPDdizszNMi=> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
COLO205 MnuxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4j3d|czKGi{cx?= MVvHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDU2xQOjB3IHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO|YYmsJGlEPTBiPTCyMlU3PyEQvF2u MkfOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
MV522 MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{WyfFczKGi{cx?= NUnle2xoT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVVZ3MkKgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS2WubD30bZRmei2JbH:gdoVi\2WwdDDiZZNm\CCjc4PhfUwhUUN3MDC9JFMvODR2IN88UU4> NETLdXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
LS1034 M4Xxe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWXIeGxlPzJiaILz NIjMeXdIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBNWzFyM{SgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS2WubD30bZRmei2JbH:gdoVi\2WwdDDiZZNm\CCjc4PhfUwhUUN3MDC9JFQvOzN7IN88UU4> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
NCI-H727 NHPSdGNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4PFXVczKGi{cx?= M4X4S2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{K3JINmdGy|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUA1Njd7OTFOwG0v NEfWfYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
COR-L23 NGTaV41Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXWwRpdOPzJiaILz MXXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDU3IuVDJ|IHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO|YYmsJGlEPTBiPTC1MlM4OyEQvF2u NE\FdYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
A549 NWTqV2xbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVuyZVc{PzJiaILz M{Ww[2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR4VtdC22aYTldk1IdG9icnXh[4VvfCCkYYPl[EBie3OjeTygTWM2OCB;IEWuPVk{KM7:TT6= NHHFTYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
NCI-H1355 MortS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkC5O|IhcHK| Ml3NS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUhzM{W1JINmdGy|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUA3NjZ6NTFOwG0v NUexbGVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
NCI-H23 NEThXXBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4jGRVczKGi{cx?= MVjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDJ|IHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO|YYmsJGlEPTBiPTC3MlEzPCEQvF2u MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
NCI-H1792 NWn3ZWZ5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlXSO|IhcHK| MYnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDF5OUKgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS2WubD30bZRmei2JbH:gdoVi\2WwdDDiZZNm\CCjc4PhfUwhUUN3MDC9JFcvOzB5IN88UU4> M2Lud|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK|5EcEWPQly8M4E,
SW1463 MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkHJO|IhcHK| NVHjb5lxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzNE[zJINmdGy|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUA6Njd{NTFOwG0v NYjzdnh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-GSK3 / GSK3 / p-PRAS40 / PRAS40 / p-FOXO / p-Casp9 / p-AKT / AKT / p-MEK / p-ERK / Erk ; 

PubMed: 24978597     


BT474 (left) and LNCaP (right) cell lines were treated with DMSO or GSK2110183 for 1 h. Western analysis was performed to assay levels of phosphorylated and total GSK-3, PRAS40, AKT and ERK, phosphorylated Foxo, Caspase 9, and MEK. Tubulin was used as a loading control. 

ATG3 / ATG12 / LC3B ; 

PubMed: 30867818     


Alterations in autophagy-related proteins induced by AKT inhibition.

24978597 30867818
In vivo Mice bearing BT474 breast tumor xenografts are dosed with afuresertib (p.o.) at 10, 30 or 100 mg/kg daily which results in 8, 37 and 61% TGI, respectively. Mice bearing SKOV3 ovarian tumor xenografts are treated with 10, 30 and 100 mg/kg afuresertib which results in 23, 37 and 97% TGI, respectively.[1]

Protocol

Kinase Assay:[1]
- Collapse

Potency (Ki*) of afuresertib:

The true potency (Ki*) of the inhibitor is initially determined at low enzyme concentrations (0.1 nM AKT1, 0.7 nM AKT2, and 0.2 nM AKT3) using a filter binding assay and then confirmed with progress curve analysis. In the filter binding assay, a pre-mix of enzyme plus inhibitor is incubated for 1 h and then added to a GSKα peptide (Ac-KKGGRARTSS-FAEPG-amide) and [γ33P] ATP. Reactions are terminated after 2 h and the radio labeled AKT peptide product is captured in a phospho-cellulose filter plate. Progress curve analysis utilizes continuous real-time fluorescence detection of product formation using the Sox-AKT-tide substrate (Ac-ARKRERAYSF-d-Pro-Sox-Gly-NH2).
Cell Research:[1]
- Collapse
  • Cell lines: Hematological cell lines and solid tumor cell lines
  • Concentrations: 30 μM
  • Incubation Time: 72 h
  • Method: A 3-day proliferation assay using CellTiter-Glo is performed to measure the growth inhibition by the compounds at 0-30 μM. Cell growth is determined relative to untreated (DMSO) controls. EC50’s are calculated from inhibition curves using a 4- or 6-parameter fitting algorithm in the Assay Client application.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female athymic nude and SCID mice bearing SKOV3 or BT474 tumors
  • Dosages: 100 mg/kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.91 mM)
Ethanol 85 mg/mL (198.91 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 427.32
Formula

C18H17Cl2FN4OS

CAS No. 1047644-62-1
Storage powder
in solvent
Synonyms N/A
Smiles CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)NC(CC3=CC(=CC=C3)F)CN)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04374630 Recruiting Drug: Paclitaxel|Drug: Afuresertib Platinum-resistant Ovarian Cancer Laekna Limited June 9 2020 Phase 2
NCT04060394 Recruiting Drug: Phase I and Phase II: LAE001/prednisone + afuresertib Metastatic Castration-resistant Prostate Cancer Laekna Limited September 13 2019 Phase 1|Phase 2
NCT02235740 Terminated Drug: Afuresertib|Drug: Carfilzomib Cancer Novartis|Amgen November 2014 Phase 1
NCT02240212 Completed Drug: Afuresertib|Drug: Paclitaxel Cancer Novartis Pharmaceuticals|Novartis October 2014 Phase 1
NCT02177682 Terminated Drug: Afuresertib Neoplasms Haematologic Novartis Pharmaceuticals|Novartis August 13 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Related Akt Products

Tags: buy Afuresertib (GSK2110183) | Afuresertib (GSK2110183) supplier | purchase Afuresertib (GSK2110183) | Afuresertib (GSK2110183) cost | Afuresertib (GSK2110183) manufacturer | order Afuresertib (GSK2110183) | Afuresertib (GSK2110183) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID